Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Better-than-expected 3Q at 'two businesses' Pfizer

This article was originally published in Scrip

Executive Summary

Like its European peer Novartis, Pfizer has reported 3Q results that beat analyst expectations. A tough quarter had been anticipated, and while revenue and earnings per share both fell by 2% compared with the same period last year, the drops were not as sharp as had been forecast. Revenues for the three months ended 30 September were $12.4bn with EPS of $0.57. Consensus estimates had put revenues at $12.25bn with EPS of $0.55.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts